Scholar Rock pulled its European application for apitegromab on Friday afternoon, shifting to an alternative manufacturing site after inspection hurdles. The withdrawal resets a key regulatory review for the spinal muscular atrophy treatment in Europe. The setback tests investor patience as the firm works toward a potential U.S. decision by September 30.

Manufacturing Hurdles Prompt Pivot